Intriguingly, analysis of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), a randomised double-blind, placebo-controlled trial investigating the role of IL-1β inhibition in atherosclerosis using the selective anti-IL-1β monoclonal antibody Canakinumab (Ilaris®), revealed that lung cancer incidence and mortality were significantly lower in Canakinumab-treated patients compared to their placebo controls. This evidence concerns the gene IL1B and lung carcinoma.